Northland Capital Partners upgraded shares of DexCom (NASDAQ:DXCM) from an under perform rating to a market perform rating in a research note released on Thursday morning, American Banking News.com reports.
Shares of DexCom (NASDAQ:DXCM) traded down 0.03% during mid-day trading on Thursday, hitting $33.04. The stock had a trading volume of 697,320 shares. DexCom has a 52 week low of $12.03 and a 52 week high of $33.87. The stock’s 50-day moving average is $28.98 and its 200-day moving average is $24.36. The company’s market cap is $2.369 billion.
DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, November 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.04. The company had revenue of $42.90 million for the quarter, compared to the consensus estimate of $35.90 million. During the same quarter in the previous year, the company posted ($0.25) earnings per share. The company’s revenue for the quarter was up 85.7% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.47 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on DXCM. Analysts at Northland Securities upgraded shares of DexCom from an underperform rating to a market perform rating in a research note to investors on Thursday. They now have a $30.00 price target on the stock, up previously from $18.00. Separately, analysts at Benchmark Co. initiated coverage on shares of DexCom in a research note to investors on Tuesday, October 15th. They set a buy rating and a $37.00 price target on the stock. Finally, analysts at Wedbush reiterated a buy rating on shares of DexCom in a research note to investors on Monday, October 14th. They now have a $31.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $29.60.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.